Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Parkinson's disease patients first treated at age 75 years or older: a comparative study.

Peretz C, Chillag-Talmor O, Linn S, Gurevich T, El-Ad B, Silverman B, Friedman N, Giladi N.

Parkinsonism Relat Disord. 2014 Jan;20(1):69-74. doi: 10.1016/j.parkreldis.2013.09.020. Epub 2013 Oct 18.

PMID:
24183677
2.

Estimation of Parkinson's disease survival in Israeli men and women, using health maintenance organization pharmacy data in a unique approach.

Chillag-Talmor O, Giladi N, Linn S, Gurevich T, El-Ad B, Silverman B, Friedman N, Peretz C.

J Neurol. 2013 Jan;260(1):62-70. doi: 10.1007/s00415-012-6584-5. Epub 2012 Jul 7.

PMID:
22772304
3.

The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.

Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL; PKDS009 Study Group.

CNS Drugs. 2004;18(11):733-46. Erratum in: CNS Drugs. 2005;19(7):633.

PMID:
15330687
4.

Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset.

Diederich NJ, Moore CG, Leurgans SE, Chmura TA, Goetz CG.

Arch Neurol. 2003 Apr;60(4):529-33.

PMID:
12707066
5.

Association of time-to-levodopa with initial Parkinsonian medication: a retrospective cohort study.

Reese JP, Hamer H, Oertel WH, Strzelczyk A, Mueller UO, Heilmaier C, Kostev K.

Int J Clin Pharmacol Ther. 2015 Feb;53(2):107-14. doi: 10.5414/CP202230.

PMID:
25546160
6.
7.

Cardiovascular and mortality risks in Parkinson's disease patients treated with entacapone.

Graham DJ, Williams JR, Hsueh YH, Calia K, Levenson M, Pinheiro SP, Macurdy TE, Shih D, Worrall C, Kelman JA.

Mov Disord. 2013 Apr;28(4):490-7. doi: 10.1002/mds.25351. Epub 2013 Feb 26.

PMID:
23443994
8.

Use of a refined drug tracer algorithm to estimate prevalence and incidence of Parkinson's disease in a large israeli population.

Chillag-Talmor O, Giladi N, Linn S, Gurevich T, El-Ad B, Silverman B, Friedman N, Peretz C.

J Parkinsons Dis. 2011;1(1):35-47. doi: 10.3233/JPD-2011-11024.

PMID:
23939255
9.

Deep brain stimulation improves survival in severe Parkinson's disease.

Ngoga D, Mitchell R, Kausar J, Hodson J, Harries A, Pall H.

J Neurol Neurosurg Psychiatry. 2014 Jan;85(1):17-22. doi: 10.1136/jnnp-2012-304715. Epub 2013 Jul 10.

PMID:
23843542
10.

Gender effect on time to levodopa-induced dyskinesias.

Hassin-Baer S, Molchadski I, Cohen OS, Nitzan Z, Efrati L, Tunkel O, Kozlova E, Korczyn AD.

J Neurol. 2011 Nov;258(11):2048-53. doi: 10.1007/s00415-011-6067-0. Epub 2011 May 1.

PMID:
21533825
11.

Levodopa-dyskinesia incidence by age of Parkinson's disease onset.

Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE.

Mov Disord. 2005 Mar;20(3):342-4.

PMID:
15580606
12.

Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project.

Uitti RJ, Ahlskog JE, Maraganore DM, Muenter MD, Atkinson EJ, Cha RH, O'Brien PC.

Neurology. 1993 Oct;43(10):1918-26.

PMID:
8413948
13.

Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis.

Olanow CW, Myllylä VV, Sotaniemi KA, Larsen JP, Pålhagen S, Przuntek H, Heinonen EH, Kilkku O, Lammintausta R, Mäki-Ikola O, Rinne UK.

Neurology. 1998 Sep;51(3):825-30.

PMID:
9748034
14.

[The use of antiparkinsonism drugs in 92 cases in Xi'an city].

Zhe X, Qu QM, Wang RL, Cao HM, Qiao J, Guo F.

Zhonghua Liu Xing Bing Xue Za Zhi. 2009 Oct;30(10):1065-8. Chinese.

PMID:
20193391
15.

Mortality associated with early and late levodopa therapy initiation in Parkinson's disease.

Scigliano G, Musicco M, Soliveri P, Piccolo I, Girotti F, Giovannini P, Caraceni T.

Neurology. 1990 Feb;40(2):265-9.

PMID:
2300246
17.

Comparison of age of onset and development of motor complications between smokers and non-smokers in Parkinson's disease.

De Reuck J, De Weweire M, Van Maele G, Santens P.

J Neurol Sci. 2005 Apr 15;231(1-2):35-9.

PMID:
15792818
18.

The natural history of Parkinson's disease in the province of Segovia: mortality in a longitudinal study (20-year follow-up).

Duarte J, García Olmos LM, Mendoza A, Clavería LE.

Acta Neurol Scand. 2013 May;127(5):295-300. doi: 10.1111/ane.12003. Epub 2012 Sep 7.

PMID:
22957805
19.

Mortality in a population-based cohort of patients treated with antiparkinsonian drugs.

Raschetti R, Spila-Alegiani S, Vanacore N, Ancona C, Meco G.

Acta Neurol Scand. 1998 Jan;97(1):20-6. Review.

PMID:
9482674
20.

Levodopa fractionation in Parkinson's disease.

Nyholm D, Stepien V.

J Parkinsons Dis. 2014;4(1):89-96. doi: 10.3233/JPD-130244.

PMID:
24398654

Supplemental Content

Support Center